LIQUIDIA CORPORATION Proceeds from Long-Term Debt Issued
LIQUIDIA CORPORATION (LQDA) reported Proceeds from Long-Term Debt Issued of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-08-12
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for the quarter ending 2025-12-31 was $0.00.
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for fiscal 2025 was $74.97M, a 30.48% increase from fiscal 2024.
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for fiscal 2024 was $57.46M, a 37.65% increase from fiscal 2023.
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for fiscal 2023 was $41.74M, a 111.18% increase from fiscal 2022.
- LIQUIDIA CORPORATION proceeds from issuance of long-term debt for fiscal 2022 was $19.77M, a 89.88% increase from fiscal 2021.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 3 month as first filed | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 6 month as first filed | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 9 month as first filed | Proceeds from Issuance of Long-term Debt 12 month | Proceeds from Issuance of Long-term Debt 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | $50.00M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $50.00M derived: sum of 3 quarters · filed 2026-08-12 | $74.97M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $50.00M derived: sum of 2 quarters · filed 2026-08-12 | $74.97M 10-Q · filed 2025-11-03 | $74.97M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $74.97M 10-Q · filed 2026-08-12 | $74.97M derived: sum of 3 quarters · filed 2026-08-12 | $107.46M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $24.98M 10-Q · filed 2026-05-11 | $24.98M derived: sum of 2 quarters · filed 2026-05-11 | $57.46M derived: sum of 3 quarters · filed 2026-05-11 | $57.46M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $32.48M derived: sum of 2 quarters · filed 2026-03-05 | $32.48M derived: sum of 3 quarters · filed 2026-03-05 | $57.46M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $32.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $32.48M derived: sum of 2 quarters · filed 2025-11-03 | $57.46M 10-Q · filed 2025-11-03 | $99.20M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $24.98M 10-Q · filed 2025-08-12 | $66.72M derived: sum of 3 quarters · filed 2026-03-05 | $66.72M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $24.98M 10-Q · filed 2025-05-08 | $66.72M derived: sum of 2 quarters · filed 2026-03-05 | $66.72M derived: sum of 3 quarters · filed 2026-03-05 | $66.72M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $41.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $41.74M derived: sum of 2 quarters · filed 2026-03-05 | $41.74M derived: sum of 3 quarters · filed 2026-03-05 | $41.74M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-08 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $0.00 derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $0.00 derived: sum of 2 quarters · filed 2024-03-13 | $0.00 derived: sum of 3 quarters · filed 2024-03-13 | $19.77M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $19.77M 10-Q · filed 2023-11-07 | $19.77M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $19.77M 10-Q · filed 2023-08-10 | $19.77M derived: sum of 3 quarters · filed 2023-08-10 | $19.77M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $19.77M 10-Q · filed 2023-05-08 | $19.77M derived: sum of 2 quarters · filed 2023-05-08 | $19.77M derived: sum of 3 quarters · filed 2023-05-08 | $19.77M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $10.41M 10-K · filed 2023-03-20 | $10.41M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $10.41M 10-Q · filed 2022-11-08 | $10.41M 10-Q · filed 2021-11-03 | $10.41M derived: sum of 4 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $10.41M 10-Q · filed 2022-08-11 | $10.41M 10-Q · filed 2021-08-10 | $10.41M derived: sum of 3 quarters · filed 2022-08-11 | $10.41M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $10.41M 10-Q · filed 2022-05-12 | $10.41M 10-Q · filed 2021-05-13 | $10.41M derived: sum of 2 quarters · filed 2022-05-12 | $10.41M derived: sum of 3 quarters · filed 2022-05-12 | $10.41M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 derived: sum of 3 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $0.00 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | $5.00M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |